Myomo to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Myomo, Inc. (NYSE American: MYO), a pioneering company in wearable medical robotics, has announced that its President and CEO, Paul Gudonis, along with CFO David Henry, will present at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. During the conference, Myomo will offer an on-demand presentation for participants, alongside opportunities for virtual one-on-one meetings with registered investors. Interested investors are encouraged to coordinate their meetings through their H.C. Wainwright representatives or by contacting the provided email.

Myomo focuses on enhancing the functionality and independence of individuals suffering from neurological disorders and upper-limb paralysis through its innovative MyoPro product line. MyoPro is a state-of-the-art powered orthosis designed specifically to assist patients with weakened or paralyzed arms due to conditions such as stroke, brachial plexus injury, traumatic brain injuries, spinal cord injuries, or other neuromuscular challenges. This groundbreaking device is unique in the U.S. market, as it employs non-invasive sensors to detect a user’s own electromyography (EMG) signals, effectively restoring their ability to perform essential daily activities, including self-feeding, carrying objects, and managing household chores.

As a result, many users of MyoPro are empowered to regain independence, return to the workforce, and significantly lower their care costs. Headquartered in Burlington, Massachusetts, Myomo operates with a dedicated team of sales and clinical professionals throughout the United States and maintains international representation. For further information about Myomo and its products, visit www.myomo.com.

As Myomo, Inc. (NYSE American: MYO) prepares for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference, investors should consider the company's unique position in the wearable medical robotics sector, especially regarding its MyoPro product line. With its ability to enhance arm and hand function for patients suffering from neurological disorders and upper-limb paralysis, Myomo is tapping into a crucial market segment characterized by increasing demand as the population ages.

The MyoPro device is currently the only marketed solution in the U.S. that utilizes non-invasive EMG sensors to support and restore limb functionality. This differentiates Myomo from competitors and positions it favorably within the medical technology industry. Given the growing emphasis on rehabilitation technologies, Myomo’s device offers significant potential benefits, including improved quality of life for users, the ability to reduce long-term healthcare costs, and enabling patients to return to work.

Investors should analyze Myomo's financial health and growth trajectory, particularly considering its ongoing clinical collaborations and potential for reimbursement pathways. The management team's participation in one-on-one meetings at the conference provides a strategic opportunity for stakeholders to gain insights into the company's future plans and financial forecasts.

Overall, Myomo stands as a compelling investment opportunity, particularly for those looking to capitalize on innovations in healthcare technology. Investors should monitor the outcomes of the conference as a potential catalyst for stock movement, especially if the company's management outlines a robust growth strategy. Additionally, keeping an eye on regulatory developments and partnership announcements will be essential as these could significantly influence Myomo's market positioning moving forward.